Incidence and impact of interstitial lung disease and malignancy in patients with polymyositis, dermatomyositis, and clinically amyopathic dermatomyositis: a retrospective cohort study

被引:36
|
作者
Ikeda, Satoshi [1 ]
Arita, Machiko [1 ]
Misaki, Kenta [2 ]
Mishima, Shohei [1 ]
Takaiwa, Takuya [1 ]
Nishiyama, Akihiro [1 ]
Ito, Akihiro [1 ]
Furuta, Kenjiro [1 ]
Yokoyama, Toshihide [1 ]
Tokioka, Fumiaki [1 ]
Noyama, Maki [1 ]
Yoshioka, Hiroshige [1 ]
Ishida, Tadashi [1 ]
机构
[1] Kurashiki Cent Hosp, Dept Resp Med, Kurashiki, Okayama 7108602, Japan
[2] Kurashiki Cent Hosp, Dept Rheumatol, Kurashiki, Okayama 7108602, Japan
来源
SPRINGERPLUS | 2015年 / 4卷
关键词
Interstitial lung disease; Malignancy; Polymyositis; Dermatomyositis; Clinically amyopathic dermatomyositis; IDIOPATHIC INFLAMMATORY MYOPATHIES; POPULATION-BASED COHORT; SINE MYOSITIS; CANCER; RISK; AUTOANTIBODIES; PNEUMONITIS; SPECTRUM; LINK;
D O I
10.1186/s40064-015-1013-8
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The aims of this study were to retrospectively review Japanese consecutive cases of polymyositis (PM), dermatomyositis (DM), and clinically amyopathic dermatomyositis (CADM), focusing on interstital lung disease (ILD) and malignancy, and to document any differences in the incidence, clinical features, and impact on prognosis among patients with PM, DM, and CADM. We retrospectively reviewed 62 consecutive patients diagnosed with PM, DM, and CADM according to Bohan and Peter's criteria (PM/DM) and Sontheimer's criteria and Gerami's criteria (CADM), focusing on ILD and malignancy. ILD occurrence rates were 48 % (11/23) in patients with PM, 46 % (11/24) in DM, and 100 % (15/15) in CADM. Malignancy occurred during diagnosis or the observation period in 14 patients; 86 % were without ILD, and 64 % were DM without ILD. Multivariate logistic regression analysis showed that the risk of newly diagnosed malignancy was significantly lower in patients with ILD [odds ratio, 0.0688; 95 % confidence interval (CI), 0.00127-0.372; p = 0.00190] and significantly higher in patients with DM (odds ratio, 5.21; 95 % CI, 1.17-23.1; p = 0.0299) than in other patients. Patients with malignancies had shorter survival than those without malignancies; no clinically meaningful difference in survival was observed among the different myositis types and for presence of ILD. In CADM-ILD, 80 % fatal cases died from refractory ILD = 90 days from the first visit; neither death nor recurrence occurred subsequently. In conclusion, a positive association between DM and malignancy and a negative association between ILD and malignancy were noted. In the present study, malignancy was a predictor of poor long-term prognosis, but ILD were not. ILD associated with CADM contributed greatly to poor short-term prognosis, but neither death nor recurrence occurred subsequently.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Pirfenidone in patients with rapidly progressive interstitial lung disease associated with clinically amyopathic dermatomyositis
    Li, Ting
    Guo, Li
    Chen, Zhiwei
    Gu, Liyang
    Sun, Fangfang
    Tan, Xiaoming
    Chen, Sheng
    Wang, Xiaodong
    Ye, Shuang
    SCIENTIFIC REPORTS, 2016, 6
  • [22] Interstitial lung disease in polymyositis and dermatomyositis
    I-Jung Chen
    Yeong-Jian Jan Wu
    Cho-Wei Lin
    Kang-Wei Fan
    Shue-Fen Luo
    Huei-Huang Ho
    Lieh-Bang Liou
    Wen-Pin Tsai
    Ji-Yih Chen
    Chung-Han Yang
    Chang-Fu Kuo
    Kuang-Hui Yu
    Clinical Rheumatology, 2009, 28 (6) : 639 - 646
  • [23] Interstitial lung disease in polymyositis and dermatomyositis
    Marie, I
    Hachulla, E
    Chérin, P
    Dominique, S
    Hatron, PY
    Hellot, MF
    Devulder, B
    Herson, S
    Levesque, H
    Courtois, H
    ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2002, 47 (06): : 614 - 622
  • [24] Interstitial lung disease in polymyositis and dermatomyositis
    Chen, I-Jung
    Wu, Yeong-Jian Jan
    Lin, Cho-Wei
    Fan, Kang-Wei
    Luo, Shue-Fen
    Ho, Huei-Huang
    Liou, Lieh-Bang
    Tsai, Wen-Pin
    Chen, Ji-Yih
    Yang, Chung-Han
    Kuo, Chang-Fu
    Yu, Kuang-Hui
    CLINICAL RHEUMATOLOGY, 2009, 28 (06) : 639 - 646
  • [25] Interstitial lung disease in polymyositis and dermatomyositis
    Hirakata, M
    Nagai, S
    CURRENT OPINION IN RHEUMATOLOGY, 2000, 12 (06) : 501 - 508
  • [26] Interstitial lung disease in polymyositis and dermatomyositis
    Fathi, M
    Lundberg, IE
    CURRENT OPINION IN RHEUMATOLOGY, 2005, 17 (06) : 701 - 706
  • [27] Interstitial Lung Disease in Polymyositis and Dermatomyositis
    Long, Kathryn
    Danoff, Sonye K.
    CLINICS IN CHEST MEDICINE, 2019, 40 (03) : 561 - +
  • [28] Intravenous cyclophosphamide for the treatment of interstitial lung disease associated with amyopathic dermatomyositis, dermatomyositis and polymyositis: A comparative study with cyclosporine and azathioprine.
    Azuma, K
    Yamasaki, Y
    Yamasaki, M
    Okubo, M
    Yamada, H
    Ozaki, S
    ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S105 - S105
  • [29] Interstitial lung disease in polymyositis/dermatomyositis [Interstitielle Lungenkrankheit bei Polymyositis/Dermatomyositis]
    Schnabel A.
    Zeitschrift für Rheumatologie, 2013, 72 (3) : 220 - 226
  • [30] Incidence and predicting factors of malignancies in 145 Japanese patients with dermatomyositis, amyopathic dermatomyositis, and polymyositis
    Azuma, K
    Ohkubo, M
    Yamada, H
    Hama, N
    Ozaki, S
    ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 : 78 - 78